Navigation Links
Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
Date:10/23/2008

ka provides us with a tremendous strategic advantage in developing novel drugs for heart failure," said James S. Kuo, M.D., M.B.A., Duska's Chairman and CEO.

About Heart Failure

Heart failure, a condition characterized by the inability of the heart to effectively pump blood as well as by fluid accumulation in the lungs and other tissues, is suffered by an estimated five million Americans and is responsible for 300,000 deaths in the U.S. annually, according to the National Heart, Lung and Blood Institute. It is the single largest Medicare expense, at a cost of $33.2 billion each year. The five-year mortality rate with heart failure can be as high as 50 percent.

About Duska Therapeutics

Duska Therapeutics, Inc. (Duska) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which by several pharmaceuticals constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Duska is developing a portfolio of investigational medicines, two of which are in late stages of clinical testing. Duska's ATPace is expected to enter a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia. Duska's CDP-1050 is expected to commence a Phase 2 clinical trial for the treatment of heart failure. In addition, Duska has a preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For more information, visit http://www.duskatherapeutics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
2. CORD:USE Cord Blood Bank is Proud to Announce that Cord Blood Pioneer and Leading Transplanter Dr. Eliane Gluckman has Joined its Team
3. ThalesNano, Inc. Forms Collaborations with Leading US Universities based on the Award Winning H-Cube(R) and H-Cube Midi(TM)
4. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
5. Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche
6. Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems
7. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
8. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
9. iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits
10. Leading AIDS Experts Urge Greater Focus on Behavior-Change Programs to Prevent HIV
11. Leading Lobbying Firm Celebrates Growth and New Name: Troutman Sanders Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Pfanstiehl has announced the launch of ... the USA under ICH ... for playing a key role in protein glycosylation.  ... that media supplementation with mannose can improve overall ... to Dr. Christopher Wilcox , VP, Business ...
(Date:10/1/2014)... (PRWEB) September 30, 2014 In ... cost-effective tools to address sales, training and consumer ... has developed innovative mobile applications to turn their ... the agency’s latest customized mobile app creations, are ... . , In partnership with Toyota, StudioPMG created ...
(Date:10/1/2014)... Francisco, California (PRWEB) October 01, 2014 ... from the National Science Foundation to expand their bioCAD/CAM ... to build and modify DNA. The Small Business Innovation ... commercialize the “j5” technology under exclusive license from the ... Joint BioEnergy Institute , an LBNL laboratory that ...
(Date:9/30/2014)... This news release is available in German . ... photonic crystal around several quantum dots in a semiconductor layer. ... a consequence of atomic processes. If a short laser pulse ... modified and the quantum dot experiences a change in the ... slow down the emission of light by the dot. As ...
Breaking Biology Technology:Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Digital Agency Studio PMG Launches New Case Studies on Website 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Ultrafast remote switching of light emission 2
... Boston Scientific Corporation (NYSE: BSX ) today ... and Drug Administration (FDA) to market its TAXUS(R) Liberte ... deliverable, next-generation drug-eluting stent (DES) specifically designed for treating ... in vessels as small as 2.25 mm in diameter ...
... Network Sciences, Inc. (GNS) today announced that it ... University of California San Francisco Cancer ... drug development across several therapeutic areas. This collaboration ... of UCSF with the computational expertise and supercomputer-driven ...
... Cell Institute (RSCI) today announced its 2009 Science Advisory Board. Once ... world-leader and has a world-first to his credit. , ... Dallas, Texas ... http://www.RepairStemCells.org , a Dallas, Texas-based stem cell global public affairs organization founded ...
Cached Biology Technology:FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 2FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 3FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 4Gene Network Sciences Announces Broad Cancer Collaboration With UCSF and Initial Results 2RSCI Announces World-Leading Stem Cell Science Advisory Board 2RSCI Announces World-Leading Stem Cell Science Advisory Board 3
(Date:9/30/2014)... want your doctor to know what goes wrong with your ... idea to know what "normal" actually is. That,s where a ... the FASEB Journal comes in. In ... key set of molecules that can help scientists "see" which ... What,s more, they found never-before-detected gene activity and that men ...
(Date:9/30/2014)... MILFORD, Mass. , Sept. 30, 2014 ... process control solutions for the biotech and ... of its new RECONN Bioprocess Manager, an ... reporting solution geared towards bioprocess development laboratories. ... facilities have disparate bioreactor and analyzer systems. ...
(Date:9/30/2014)... of The Economist,s prestigious Innovation awards 2014 will speak ... the JW Marriott Hong Kong on Friday, October 10 th ... and the lessons those hold for others. The awards, which recognises ... decade, will be presented at a ceremony in Hong ... the first time the ceremony has come to Asia ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Spectra Automation Introduces RECONN Bioprocess Manager 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... the largest international study to date into the genetic basis ... disease and provide evidence that large-scale genetic studies can assist ... as rheumatoid arthritis. The study, conducted by Dr. Robert ... Institute in the USA and Dr. Yukinori Okada from the ...
... a recent study published in the Neural Regeneration ... Li and team from Zhongshan School of Medicine, Sun ... BACE1, the key enzyme in amyloid beta protein (Aβ) ... construct a short hairpin (shRNA) expression plasmid against the ...
... is in ideal cardiovascular health, according to the new CANHEART ... CMAJ ( Canadian Medical Association Journal ). Cardiovascular ... leading cause of death in Canada. "A large proportion ... trend has not changed in the past decade," says senior ...
Cached Biology News:Rheumatoid arthritis research shows the potential of large-scale genetic studies for drug discovery 2Fewer than 1 in 10 Canadians in ideal cardiovascular health 2Fewer than 1 in 10 Canadians in ideal cardiovascular health 3
... The AccuSpot automates LC microfractionaction, spotting and ... the AccuSpot system, LC eluent can be ... in trace amounts (eg.50nl). Matrix solutions can ... preparation of target plated for MALDI-TOF-MS measurements. ...
Glycerokinase; from Bacillus stearothermophilus...
PTFE/red rubber septum silver aluminum seal ,11 mm seal diam. ...
...
Biology Products: